Health professionals discussing a new treatment for restless legs syndrome with patients can refer to the latest edition of NPS RADAR for important counselling points. Pramipexole (Sifrol) should be reserved for patients with severe primary cases of restless legs syndrome as the benefits of use are relatively modest, NPS recommends in the latest edition of NPS RADAR. The review of the recently listed PBS item includes an 'information for patients' section to assist with counselling patients.

According to NPS Deputy CEO, Karen Kaye, restless legs can be severe and distressing for some patients who may benefit from drug treatment for their symptoms, but for others the risk of adverse events outweigh the benefits of use…